Var2 Pharmaceuticals has been selected as the European winner of the 2020 Advance Biotech Grant Program (SigmaMillipore). VAR2 Pharmaceuticals was chosen for its development of a promising novel pre-clinical cancer drug-conjugate treatment with the potential to treat multiple types of human adult and childhood solid tumors.